Active, not recruitingPhase 2NCT05690386
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
Studying Turner syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Intervention
- Lonapegsomatropin(biological)
- Enrollment
- 48 enrolled
- Eligibility
- 1-10 years · FEMALE
- Timeline
- 2023 – 2027
Study locations (19)
- Ascendis Pharma Investigational Site, Palo Alto, California, United States
- Ascendis Pharma Investigational Site, San Diego, California, United States
- Ascendis Pharma Investigational Site, Aurora, Colorado, United States
- Ascendis Pharma Investigational Site, Orlando, Florida, United States
- Ascendis Pharma Investigational Site, St. Petersburg, Florida, United States
- Ascendis Pharma Investigational Site, Atlanta, Georgia, United States
- Ascendis Pharma Investigational Site, Idaho Falls, Idaho, United States
- Ascendis Pharma Investigational Site, Chicago, Illinois, United States
- Ascendis Pharma Investigational Site, Boston, Massachusetts, United States
- Ascendis Pharma Investigational Site, Saint Paul, Minnesota, United States
- Ascendis Pharma Investigational Site, Las Vegas, Nevada, United States
- Ascendis Pharma Investigational Site, Lake Success, New York, United States
- Ascendis Pharma Investigational Site, Chapel Hill, North Carolina, United States
- Ascendis Pharma Investigational Site, Cincinnati, Ohio, United States
- Ascendis Pharma Investigational Site, Oklahoma City, Oklahoma, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05690386 on ClinicalTrials.govOther trials for Turner syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07502586Turner Syndrome: Genetic ConsiderationsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- RECRUITINGPHASE3NCT07221851Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient DisordersAscendis Pharma A/S
- RECRUITINGNCT07344012Parental Project Amongst 93 Patients With Turner SyndromeUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06834594Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner SyndromeChildren's Mercy Hospital Kansas City
- RECRUITINGNCT06507007Genetic and Epigenetic Background of Inner Ear Dysfunction in Turner SyndromeGødstrup Hospital
- RECRUITINGNCT06794190Characterization of Hepatopathy in Turner Syndrome: Analysis of DeterminantsIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06668805A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentBioMarin Pharmaceutical
- RECRUITINGPHASE2NCT05849389Vosoritide for Short Stature in Turner SyndromeRoopa Kanakatti Shankar, MBBS, MS